RELEASE DATE: OCTOBER 2, 2020
Amy Feehan, PhD, was recently awarded NIH federal funds from the Louisiana Clinical and Translational Science (LA CaTS) Center for her study titled “Developing a bile acid biomarker to predict the efficacy of fecal microbiota transplantation in overt hepatic encephalopathy.”
This grant will enable the analysis of blood samples from patients who have hepatic encephalopathy (HE), a cognitive disorder caused by cirrhosis of the liver. The grant will enable Dr. Feehan to work with colleagues at Duke and Tulane Universities to determine whether compounds in the blood can predict whether someone with HE will benefit from the treatment or not. This information could be used for a more personalized approach to therapy.
This is the first time an Ochsner investigator received a LA CaTS pilot grant.
